BACKGROUND: Pancreatic carcinoma is associated with a poor prognosis. The aim of this study was to determine whether glucose metabolism in pancreatic cancer has prognostic significance for patients suffering from this disease. METHODS: The survival data of 52 patients with pancreatic carcinoma was correlated with the standardized uptake value (SUV) as a semiquantitative parameter of glucose metabolism, as determined with fluorodeoxyglucose positron emission tomography (FDG PET). A multivariate analysis, including SUV and accepted factors of prognosis, such as stage at presentation and tumor marker Ca 19-9, was performed to determine the prognostic value of FDG PET. RESULTS: The median survival in 26 patients with low SUV (< 6.1) was 9 months (95% confidence interval 6-12 months) vs. 5 months (95% confidence interval 4-6 months) in 26 patients with high SUV (> or = 6.1). Multivariate analysis revealed SUV and tumor marker Ca 19-9 as independent factors of prognosis in patients with pancreatic carcinoma. CONCLUSION: Glucose metabolism, as determined with FDG PET, provides additional prognostic information in patients with pancreatic carcinoma.
BACKGROUND:Pancreatic carcinoma is associated with a poor prognosis. The aim of this study was to determine whether glucose metabolism in pancreatic cancer has prognostic significance for patients suffering from this disease. METHODS: The survival data of 52 patients with pancreatic carcinoma was correlated with the standardized uptake value (SUV) as a semiquantitative parameter of glucose metabolism, as determined with fluorodeoxyglucose positron emission tomography (FDG PET). A multivariate analysis, including SUV and accepted factors of prognosis, such as stage at presentation and tumor marker Ca 19-9, was performed to determine the prognostic value of FDG PET. RESULTS: The median survival in 26 patients with low SUV (< 6.1) was 9 months (95% confidence interval 6-12 months) vs. 5 months (95% confidence interval 4-6 months) in 26 patients with high SUV (> or = 6.1). Multivariate analysis revealed SUV and tumor marker Ca 19-9 as independent factors of prognosis in patients with pancreatic carcinoma. CONCLUSION:Glucose metabolism, as determined with FDG PET, provides additional prognostic information in patients with pancreatic carcinoma.
Authors: Chakshu Sharma; Karim M Eltawil; Paul D Renfrew; Mark J Walsh; Michele Molinari Journal: World J Gastroenterol Date: 2011-02-21 Impact factor: 5.742
Authors: Minsig Choi; Lance K Heilbrun; Raghu Venkatramanamoorthy; Jawana M Lawhorn-Crews; Mark M Zalupski; Anthony F Shields Journal: Am J Clin Oncol Date: 2010-06 Impact factor: 2.339
Authors: Ibane Abasolo; Judit Pujal; Rosa M Rabanal; Anna Serafin; Pilar Navarro; Olga Millán; Francisco X Real Journal: Eur J Nucl Med Mol Imaging Date: 2009-02-28 Impact factor: 9.236